Where is the most reliable place to buy Platinib?

Introduction: Platinib is a selective rearrangement during transfection (RET) inhibitor that is being developed for the treatment of various solid tumors. RET is a well-described proto-oncogene present in a variety of cancers, including non-small cell lung cancer (NSCLC), papillary thyroid carcinoma, and medullary thyroid carcinoma (MTC).

Where to buy Platinib more reliably

1. Hospital pharmacy: Patients can purchase the required directly at the hospital pharmacy under the advice of the doctor. The patient usually needs to provide a prescription before purchasing it in the hospital pharmacy.

2. Professional drug retailers: Some professional drug retailers also provide sales services for Platinib. These retailers often have direct relationships with pharmaceutical companies and can also purchase the drugs they need.

3. Online drug platforms: With the popularization of the Internet, patients can purchase platinib through some legal and formal online drug platforms. This method of purchasing drugs is more convenient and saves time, but patients need to ensure the legality and credibility of the platform to prevent the purchase of fake and inferior drugs.

The mechanism of action of Platinib

Pralsetinib is a once-daily oral precision treatment drug that selectively targets cancer-causing RET mutations. Platinib is a low-concentration kinase inhibitor of wild-type RET and oncogenic RET fusion (CCDC6-RET) and mutant (RET V804L, RET V804M, and RET M918T) kinases with half-maximal inhibitory concentrations (IC50s) of less than 0.5 nM. The drug specifically inhibits RET changes that lead to a variety of cancers.

Platinib has demonstrated anticancer activity in cultured cells and animal tumor implant models, including oncogenic RET fusions or mutations, such as KIF5B-RET, CCDC6-RET, RET M918 T, RET C634W, RET V804E, RET V804L, and RETV804M.

Platinib Efficacy Study

A global Phase 1/2 trial to evaluate the safety, tolerability and efficacy of Platinib in patients with RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC), and other advanced solid tumors with RET fusions.

Among 68 patients who did not receive treatment, the overall response rate (ORR) was 79%, the complete response (CR) rate was 6%, 10% of patients had complete regression of the target tumor, and 74% of patients had a partial response (PR). The median duration of response (DOR) was not reached. Among 126 patients who had previously received platinum-based chemotherapy, the ORR was 62%, the CR rate was 4%, 12% of patients had complete regression of target tumors, and 58% of patients had PR. The median DOR was 22.3 months. was good.